- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00298987
A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate
February 4, 2010 updated by: Bristol-Myers Squibb
Study of Dasatinib (BMS-354825) in Subjects With Chronic Myelogenous Leukemia With Accelerated or Myeloid or Lymphoid Blast Phase or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant to or Intolerant of Imatinib Mesylate
The purpose of this clinical research study is to provide dasatinib treatment to patients with advanced chronic myelogenous leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who no longer can tolerate treatment with imatinib.
The safety of the treatment will also be studied.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
400
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada
- Local Institution
-
-
British Columbia
-
Vancouver, British Columbia, Canada
- Local Institution
-
-
Ontario
-
Hamilton, Ontario, Canada
- Local Institution
-
Toronto, Ontario, Canada
- Local Institution
-
-
Quebec
-
Montreal, Quebec, Canada
- Local Institution
-
-
-
-
California
-
Corona, California, United States
- Local Institution
-
-
Colorado
-
Aurora, Colorado, United States
- Local Institution
-
Colorado Springs, Colorado, United States
- Local Institution
-
-
Connecticut
-
Waterford, Connecticut, United States
- Local Institution
-
-
Florida
-
Daytona Beach, Florida, United States
- Local Institution
-
Jupiter, Florida, United States
- Local Institution
-
-
Georgia
-
Atlanta, Georgia, United States
- Local Institution
-
Lawrenceville, Georgia, United States
- Local Institution
-
-
Indiana
-
Beach Grove, Indiana, United States
- Local Institution
-
Indianapolis, Indiana, United States
- Local Institution
-
-
Iowa
-
Iowa City, Iowa, United States
- Local Institution
-
-
Kansas
-
Kansas City, Kansas, United States
- Local Institution
-
Salina, Kansas, United States
- Local Institution
-
-
Kentucky
-
Lexington, Kentucky, United States
- Local Institution
-
Louisville, Kentucky, United States
- Local Institution
-
-
Massachusetts
-
Boston, Massachusetts, United States
- Local Institution
-
-
Michigan
-
Ann Arbor, Michigan, United States
- Local Institution
-
Detroit, Michigan, United States
- Local Institution
-
-
New Mexico
-
Santa Fe, New Mexico, United States
- Local Institution
-
-
New York
-
New York, New York, United States
- Local Institution
-
-
Ohio
-
Cincinnati, Ohio, United States
- Local Institution
-
Cleveland, Ohio, United States
- Local Institution
-
-
Oklahoma
-
Lawton, Oklahoma, United States
- Local Institution
-
Tulsa, Oklahoma, United States
- Local Institution
-
-
Oregon
-
Portland, Oregon, United States
- Local Institution
-
-
Rhode Island
-
Providence, Rhode Island, United States
- Local Institution
-
-
South Carolina
-
Charleston, South Carolina, United States
- Local Institution
-
-
Tennessee
-
Chattanooga, Tennessee, United States
- Local Institution
-
-
Washington
-
Spokane, Washington, United States
- Local Institution
-
-
Wisconsin
-
Sheboygan, Wisconsin, United States
- Local Institution
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of accelerated phase or blast phase CML or Ph+ ALL
- Intolerant or resistant to imatinib mesylate
- 18 years of age or older
- ECOG performance 0-2 (greater than 50% of time out of bed)
- Adequate liver and kidney function
Exclusion Criteria:
- Pregnant or breastfeeding females
- History of significant cardiac disease
- History of significant bleeding disorder (not CML)
- Prisoners
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A1
|
Tablets, Oral, 70 mg, Twice daily, 2 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Provide therapy to patients for which there is no therapeutic alternative
|
Secondary Outcome Measures
Outcome Measure |
---|
Safety data collection
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2006
Primary Completion (Actual)
June 1, 2007
Study Completion (Actual)
June 1, 2007
Study Registration Dates
First Submitted
March 2, 2006
First Submitted That Met QC Criteria
March 3, 2006
First Posted (Estimate)
March 6, 2006
Study Record Updates
Last Update Posted (Estimate)
February 8, 2010
Last Update Submitted That Met QC Criteria
February 4, 2010
Last Verified
June 1, 2008
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Leukemia
- Leukemia, Myeloid
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Dasatinib
Other Study ID Numbers
- CA180-033
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia, Myeloid, Chronic
-
Newcastle UniversityBristol-Myers Squibb; Institute of Cancer Research, United Kingdom; Newcastle-upon-Tyne... and other collaboratorsCompletedMyeloid Leukemia, Chronic, Chronic PhaseUnited Kingdom
-
Asan Medical CenterTerminatedLeukemia, Chronic Myeloid | Myeloid Leukemia, Chronic, Chronic Phase | Myeloid Leukemia, Chronic, Accelerated PhaseKorea, Republic of
-
Bristol-Myers SquibbTerminatedLeukemia, Myeloid, ChronicSweden, United Kingdom, Russian Federation, France, Germany, Belgium, Portugal, Finland, Norway, Spain, Italy
-
University of BolognaCompletedMyeloid Leukemia, Chronic, Chronic-PhaseItaly
-
Bristol-Myers SquibbWithdrawnMyeloid Leukemia, Chronic, Chronic-PhaseUnited States
-
PETHEMA FoundationCompleted
-
H. Lee Moffitt Cancer Center and Research InstituteIncyte Corporation; H. Jean Khoury Cure CML ConsortiumRecruitingChronic Myeloid Leukemia, Chronic Phase | Chronic Phase Chronic Myeloid LeukemiaUnited States
-
Emory UniversityTerminatedLeukemia | Chronic Myeloid Leukemia | Chronic Myelogenous LeukemiaUnited States
-
Fundacion Espanola para la Curacion de la Leucemia...Pfizer; Roche Farma, S.ATerminatedChronic Phase-Chronic Myeloid LeukemiaSpain
-
TakedaActive, not recruitingMyeloid Leukemia, Chronic, Chronic PhaseUnited States, Spain, Taiwan, Australia, Canada, Russian Federation, Sweden, Switzerland, Germany, United Kingdom, Poland, Korea, Republic of, Argentina, Hong Kong, Singapore, Italy, Chile, Czechia, Denmark, France, Portugal
Clinical Trials on Dasatinib
-
Bristol-Myers SquibbCompletedPharmacokinetic Study in Healthy ParticipantsUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Completed
-
Hyoung Jin KangNot yet recruitingAcute Lymphoblastic Leukemia, Pediatric
-
National Cancer Institute (NCI)WithdrawnHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell MyelomaUnited States
-
National Cancer Institute (NCI)NRG OncologyTerminatedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Recurrent Uterine Corpus CancerUnited States
-
Xspray Pharma ABQPS Bioserve India Pvt LimitedCompleted
-
Peking University Cancer Hospital & InstituteUnknownGastrointestinal Stromal TumorChina
-
Kanto CML Study GroupUnknownMyelogenous Leukemia, Chronic, Chronic PhaseJapan
-
Jonsson Comprehensive Cancer CenterBristol-Myers SquibbCompleted
-
Swiss Group for Clinical Cancer ResearchCompletedGastrointestinal Stromal TumorFrance, Switzerland, Germany, Finland